CEO Executive AssistantFDA regulatory submissions represent defining moments in the lifecycle of a medical device company. A 510(k) clearance, a PMA approval, a De Novo authorization, or a significant device modification submission can determine whether a product reaches market, how quickly, and under what conditions. For the medical device CEO, these submission periods concentrate strategic, financial, operational, and external communication demands in ways that few other business events can match.
The time management challenge is substantial. Regulatory submissions require significant organizational preparation that touches clinical, regulatory, quality, engineering, and commercial functions simultaneously. The CEO needs to be engaged enough to ensure that the submission reflects the company’s strategic priorities and that organizational resources are adequate to execute the process well. But the CEO’s engagement must be calibrated to avoid substituting for the regulatory expertise that the submission actually requires.
The CEO’s Contribution to Regulatory Submission Strategy
Regulatory strategy is a domain where CEO involvement is genuinely valuable but must be appropriately bounded.
The CEO’s unique contribution includes: authorizing the resource commitment required for a high-quality submission, ensuring that the regulatory strategy aligns with the company’s commercial objectives and timeline priorities, communicating with the board and investors about the regulatory process and timeline, and engaging with the FDA at the executive relationship level where appropriate.
What the CEO does not contribute: the technical content of the submission, the detailed response to FDA deficiency letters, the management of the submission preparation timeline, or the day-to-day interaction with the FDA review division. These belong to your regulatory affairs team and, for PMA submissions, typically involve specialized regulatory counsel and clinical development expertise.
The most common CEO time management error during regulatory submissions is attempting to substitute executive judgment for regulatory expertise. CEOs who review submission documents line by line, attend all regulatory team meetings, and attempt to personally manage FDA relationships at the operational level consume significant time without improving submission quality.
Establishing the Regulatory Oversight Cadence
For a major regulatory submission, establish a structured oversight cadence from the beginning of the preparation process through receipt of the FDA decision.
A monthly regulatory leadership review: 60 minutes with your VP or head of regulatory affairs, CMO or chief clinical officer, and VP of quality. This meeting covers submission preparation progress versus timeline, any emerging issues that could affect the submission’s quality or timeline, FDA pre-submission interaction status, and any resource or organizational issues requiring CEO resolution.
This monthly meeting is the CEO’s primary governance mechanism during the preparation period. It should cover strategic-level issues, not technical preparation details. If the conversation is dominated by content decisions that belong to your regulatory team, the meeting’s purpose has drifted from governance to operations.
Between monthly meetings, receive a bi-weekly written status update from your head of regulatory affairs: a brief summary of preparation progress, any FDA interactions, and any emerging issues requiring CEO awareness. Review this update asynchronously and respond only when action is required.
Managing the Board and Investor Dimension
Regulatory submissions significantly affect investor and board expectations because they represent a binary outcome with major financial implications. The FDA’s decision determines whether commercial revenue can begin, how the company will be valued, and whether partnership or financing conversations can progress on their current trajectory.
This investor and board interest creates significant CEO time demand during submission periods. Managing it efficiently requires proactive, structured communication that reduces the volume of individual inquiries without limiting substantive engagement.
For the board, establish a quarterly regulatory update that provides current status, timeline expectations, and an honest assessment of risks and contingencies. This standing update, combined with a clear notification protocol for significant regulatory developments (FDA requests for additional information, meeting notifications, and decision receipt), satisfies board oversight needs without requiring multiple ad hoc board conversations.
For investors, the same proactive communication principle applies. A quarterly investor update letter that covers regulatory progress, prepared by your investor relations team and reviewed by you, reduces the volume of individual investor calls while maintaining appropriate communication. For your most significant investors, direct CEO calls at key milestones (submission filing, FDA acceptance, significant correspondence receipt) maintain the relationship quality that key investors value.
Work with your executive assistant for healthcare CEO to schedule investor and board communication preparation as standing calendar commitments during submission periods, ensuring that these communication obligations are managed efficiently rather than managed reactively under time pressure.
FDA Executive Relationships: When CEO Engagement Adds Value
The FDA review process is a technical process managed by review divisions with specific scientific and regulatory expertise. Most FDA interaction during a submission review appropriately occurs between your regulatory team and the FDA reviewer, not at the CEO level.
However, there are moments when CEO-level FDA engagement creates genuine value.
During a pre-submission meeting or Type B meeting on a complex regulatory strategy question, CEO presence communicates organizational commitment and allows the CEO to directly understand the FDA’s perspective on the regulatory approach, which can improve strategic decisions about the submission’s design.
If the submission results in a major deficiency letter or complete response letter requiring significant organizational response, CEO engagement in the strategic response decision is appropriate. What is the company’s regulatory strategy in response to the FDA’s concerns? Does the response require additional clinical data, device design modifications, or manufacturing changes that have significant resource and timeline implications?
During rare formal dispute resolution or appeal processes, CEO-level engagement may be warranted depending on the significance of the decision being contested.
For most submission periods, however, the CEO’s FDA relationship exists at the level of organizational credibility rather than operational interaction. Your regulatory team’s professional reputation, your submission’s quality, and your organization’s history of regulatory compliance are the primary drivers of FDA’s engagement quality. Building these organizational credentials is a longer-term investment that no individual CEO-to-reviewer relationship can substitute for.
Pre-Submission Strategy: The Highest-Value CEO Investment
The period before a major submission, particularly before the first interaction with the FDA on a significant regulatory question, is where CEO time investment produces the highest return.
Pre-submission FDA interactions, whether a Q-sub (pre-submission meeting request) or informal early communication with the review division, can dramatically improve the quality of a subsequent formal submission by surfacing FDA concerns before the submission is filed. Engaging in these pre-submission interactions requires strategic decisions about what to ask, how to frame the questions, and how to represent the company’s regulatory intentions.
Reserve two to four hours for deep involvement in the pre-submission strategy: reviewing the pre-sub request document, working with your regulatory team on the key questions to raise, and preparing for the pre-submission meeting if one is granted. This investment pays dividends in a more precisely targeted formal submission with fewer potential deficiencies.
Research from the Journal of the American Medical Association on medical device regulatory pathways highlights the significant variance in FDA review timelines and outcomes based on submission quality and pre-submission alignment. CEO investment in the strategic dimensions of submission preparation, rather than only the governance oversight, directly affects these outcomes.
Managing the Waiting Period
The period between submission filing and FDA decision can range from months for 510(k)s to years for PMA applications. Managing the CEO’s time and the organization’s attention during this waiting period requires deliberate structure.
First, the organization should not operate in suspended animation during the review period. Commercial preparation, manufacturing scale-up, partnership development, and the development of subsequent products all should proceed on their independent timelines, informed by regulatory contingency planning but not held hostage to the pending decision.
Second, the CEO’s time allocation should normalize after submission filing. The intensified regulatory involvement of the pre-submission and submission period should give way to the monthly oversight cadence described above, freeing your time for the other strategic priorities that the submission period may have partially displaced.
Third, maintain a communications readiness posture for when the FDA decision arrives. Prepare in advance the board communication, investor communication, and internal communication you will deliver on the day of decision receipt. Having these prepared reduces the reactive chaos that an unprepared receipt of an FDA decision, positive or negative, can generate.
Responding to FDA Deficiency Letters
If the FDA issues a deficiency letter, additional information request, or complete response letter, the regulatory response preparation is among the most time-intensive events in the CEO’s calendar for that period.
The CEO’s response-period time investment has three components. First, strategic decision-making: What is the company’s response strategy? Does the FDA’s concern require a clinical study, a device modification, a manufacturing change, or a regulatory argument? These strategic decisions require CEO-level judgment about resource commitment, timeline implications, and commercial consequences.
Second, resource authorization: A major regulatory response often requires significant additional investment. Authorizing these resources quickly is a CEO function with material timeline implications.
Third, board and investor communication: FDA deficiency letters create board and investor concern that requires CEO-level communication. A proactive, candid explanation of the FDA’s concern and the company’s response strategy, delivered promptly after receipt, is the most effective approach.
Apply productivity tools for healthcare CEOs to structure your information management during response periods, ensuring that the complex information flows between regulatory, clinical, and executive teams are organized rather than managed through ad hoc communications.
The Post-Approval Phase: New CEO Time Demands
FDA clearance or approval creates a new set of CEO time demands: commercial launch preparation, manufacturing scale-up authorization, post-market surveillance program establishment, and the investor and stakeholder communication surrounding the regulatory success.
Plan for these post-approval demands before the decision arrives. Build launch readiness into your organizational preparation so that regulatory success triggers a coordinated organizational response rather than a reactive scramble. The CEO who arrives at approval day with a clear launch plan, a prepared board communication, and a coordinated commercial team extracts significantly more value from the regulatory event than the one who is still organizing the organizational response after the fact.
Related Reading
For further context, explore How Medical Device CEOs Manage Time During a Major Product Launch and Adapting the Pomodoro Technique for the Demands of a Healthcare Executive.